^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mesothelioma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The NCCN Panel recommends (category 2A) adding bevacizumab to carboplatin/pemetrexed with or without maintenance bevacizumab as first-line therapy option for patients with unresectable MPM… Mesothelioma: Peritoneal….FIRST-LINE THERAPY...Cisplatin + pemetrexed + bevacizumab….Preferred (if nivolumab/ipilimumab first line)...Cisplatin + pemetrexed + bevacizumab
    Secondary therapy:
    cisplatin + pemetrexed; carboplatin + pemetrexed